share_log

Invivyd | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deep Track Capital, LP(9.17%),Deep Track Biotechnology Master Fund, Ltd.(9.17%), etc.

Invivyd | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deep Track Capital, LP(9.17%),Deep Track Biotechnology Master Fund, Ltd.(9.17%), etc.

Invivyd | SC 13G/A：超過5%持股股東披露文件(修正)-Deep Track Capital, LP(9.17%),Deep Track Biotechnology Master Fund, Ltd.(9.17%)等
美股SEC公告 ·  11/14 22:22

Moomoo AI 已提取核心訊息

On September 30, 2024, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a shared voting and dispositive power over 10,953,937 shares of Invivyd, Inc. This represents a 9.17% stake in the company's common stock. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons not seeking to control or influence the company but who hold more than 5% of a class of securities. The shares in question are based on 119,442,635 common stock outstanding as of August 1, 2024, according to Invivyd's Form 10-Q filed on August 14, 2024. The filing also includes a certification by David Kroin, stating that the shares were not acquired for the purpose of changing or influencing the control of Invivyd, Inc. and were not held in connection with any transaction having that purpose or effect.
On September 30, 2024, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a shared voting and dispositive power over 10,953,937 shares of Invivyd, Inc. This represents a 9.17% stake in the company's common stock. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons not seeking to control or influence the company but who hold more than 5% of a class of securities. The shares in question are based on 119,442,635 common stock outstanding as of August 1, 2024, according to Invivyd's Form 10-Q filed on August 14, 2024. The filing also includes a certification by David Kroin, stating that the shares were not acquired for the purpose of changing or influencing the control of Invivyd, Inc. and were not held in connection with any transaction having that purpose or effect.
2024年9月30日，深跟蹤資本有限合夥公司、深追蹤生物技術主基金有限公司和大衛·克羅因向美國證券交易委員會提交了一份修訂後的13G/A表格，表明他們共同持有Invivyd股份公司的10,953,937股的表決權和處分權，這代表了該公司普通股的9.17%。該提交是根據1934年證券交易法案的13d-1(c)規定進行的，該規定適用於持有某一類證券超過5%但不尋求控制或影響公司的人。有關股份基於2024年8月1日，根據Invivyd於2024年8月14日提交的10-Q表格顯示的119,442,635股普通股。該提交還包括大衛·克羅因的聲明，表示這些股份並非爲了改變或影響Invivyd股份公司的控制權，也不是爲了與具有該目的或效果的任何交易相關聯而持有。
2024年9月30日，深跟蹤資本有限合夥公司、深追蹤生物技術主基金有限公司和大衛·克羅因向美國證券交易委員會提交了一份修訂後的13G/A表格，表明他們共同持有Invivyd股份公司的10,953,937股的表決權和處分權，這代表了該公司普通股的9.17%。該提交是根據1934年證券交易法案的13d-1(c)規定進行的，該規定適用於持有某一類證券超過5%但不尋求控制或影響公司的人。有關股份基於2024年8月1日，根據Invivyd於2024年8月14日提交的10-Q表格顯示的119,442,635股普通股。該提交還包括大衛·克羅因的聲明，表示這些股份並非爲了改變或影響Invivyd股份公司的控制權，也不是爲了與具有該目的或效果的任何交易相關聯而持有。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    180 Life Sciences
    ATNF
    -- 2.900
    Clearmind Medicine
    CMND
    -- 1.7200
    Theriva Biologics
    TOVX
    -- 1.7600
    Anebulo Pharmaceuticals
    ANEB
    -- 1.620
    Polyrizon
    PLRZ
    -- 2.080

    解鎖榜首股票